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Strengths and limitations of this study
 ► This validation study was able to compare prediction 
performance Global Anticoagulant Registry in the 
FIELD- Atrial Fibrillation model versus CHA2DS2VASc 
for stroke and HAS- BLED for major bleeding in pa-
tients with atrial fibrillation.
 ► This study used a large contemporary population- 
based cohort with atrial fibrillation with many events 
and very limited loss to follow- up.
 ► The validation was based on International 
Classification of Diseases, Tenth Revision coding 
from the Danish registries which is prone to misclas-
sification bias and lacked clinical measurements.
AbStrACt
Objectives To externally validate the accuracy of the 
Global Anticoagulant Registry in the FIELD- Atrial Fibrillation 
(GARFIELD- AF) model against existing risk scores for 
stroke and major bleeding risk in patients with non- 
valvular AF in a population- based cohort.
Design Retrospective cohort study.
Setting Danish nationwide registries.
Participants 90 693 patients with newly diagnosed non- 
valvular AF were included between 2010 and 2016, with 
follow- up censored at 1 year.
Primary and secondary outcome measures External 
validation was performed using discrimination and 
calibration plots. C- statistics were compared with 
CHA2DS2VASc score for ischaemic stroke/systemic 
embolism (SE) and HAS- BLED score for major bleeding/
haemorrhagic stroke outcomes.
results Of the 90 693 included, 51 180 patients received 
oral anticoagulants (OAC). Overall median age (Q1, Q3) 
were 75 (66–83) years and 48 486 (53.5%) were male. 
At 1- year follow- up, a total of 2094 (2.3%) strokes/SE, 
2642 (2.9%) major bleedings and 10 915 (12.0%) deaths 
occurred. The GARFIELD- AF model was well calibrated 
with the predicted risk for stroke/SE and major bleeding. 
The discriminatory value of GARFIELD- AF risk model 
was superior to CHA2DS2VASc for predicting stroke in the 
overall cohort (C- index: 0.71, 95% CI: 0.70 to 0.72 vs 
C- index: 0.67, 95% CI: 0.66 to 0.68, p<0.001) as well as 
in low- risk patients (C- index: 0.64, 95% CI: 0.59 to 0.69 
vs C- index: 0.57, 95% CI: 0.53 to 0.61, p=0.007). The 
GARFIELD- AF model was comparable to HAS- BLED in 
predicting the risk of major bleeding in patients on OAC 
therapy (C- index: 0.64, 95% CI: 0.63 to 0.66 vs C- index: 
0.64, 95% CI: 0.63 to 0.65, p=0.60).
Conclusion In a nationwide Danish cohort with non- 
valvular AF, the GARFIELD- AF model adequately predicted 
the risk of ischaemic stroke/SE and major bleeding. Our 
external validation confirms that the GARFIELD- AF model 
was superior to CHA2DS2VASc in predicting stroke/SE 
and comparable with HAS- BLED for predicting major 
bleeding.
IntrODuCtIOn
Atrial fibrillation (AF) is a common cardiac 
arrhythmia with a lifetime prevalence of 
20%–30% and is the cause of one in four 
strokes.1 AF is associated with an increased 
risk of several cardiovascular conditions, most 
notably a nearly fivefold increased stroke risk.2 3 
The risk of stroke can be substantially dimin-
ished by thrombotic prophylaxis.4 5 However, 
20%–40% of potentially eligible patients 
do not receiving oral anticoagulant (OAC) 
therapy.6–8 The most important and modi-
fiable contributing factor is inappropriate 
risk assessment, with underutilisation of 
existing risk scores, resulting in overestima-
tion of bleeding risks and underestimation 
of potential stroke risk.9 10 Recently, the 
Global Anticoagulant Registry in the FIELD- 
Atrial Fibrillation (GARFIELD- AF) model 
was developed that allowed for simultaneous 
calculation of death, stroke and bleeding 
risks in an international prospective registry 
of patients with newly diagnosed AF.11 In the 
GARFIELD- AF and ORBIT- AF registries, the 
GARFIELD- AF model was found to improve 
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discrimination of the existing risk scores for stroke 
(CHA2DS2- VASc) and bleeding (HAS- BLED).
11–13 These 
registries may not cover the full spectrum of patients with 
AF, which warrants external validation of these risk scores 
in other population- based cohorts. We aimed to (1) 
externally validate the GARFIELD- AF model of ischaemic 
stroke and major bleeding outcomes among patients 
with newly diagnosed AF in a large contemporary Danish 
cohort and (2) perform a head- to- head comparison of 
the predictive properties of GARFIELD- AF model with 
CHA2DS2- VASc for thromboembolic events and HAS- 
BLED for major bleeding. We did not externally validate 
the GARFIELD- AF model for risk of death, as we did not 
have blood pressure and heart rate measurements; covari-
ates that the GARFIELD- AF model for death requires.
MAterIAlS AnD MethODS
We reported our findings according to the transparent 
reporting of a multivariable prediction model for indi-
vidual prognosis or diagnosis criteria.14
Data sources
We used the Danish nationwide registers cross- linking 
The Civil Registration System, The Danish National 
Patient Register (DNPR) and The Danish Drug Statis-
tical Registry. The Civil Registration System holds data 
on age, sex and vital status. DNPR contains all hospital 
admissions according to International Classification of 
Diseases, Tenth Revision (ICD-10) and procedures. The 
Danish Drug Statistical Registry was used to characterise 
pharmacotherapy in which all claimed drug prescriptions 
are registered. To compare characteristics (baseline and 
outcomes) of the Danish registry, we used data from the 
GARFIELD- AF registry which, in brief, is an observational, 
multicentre, international study of newly diagnosed AF 
with ≥1 risk factor for stroke.15
Study population
From the DNPR, patients aged ≥18 years with a primary 
or secondary diagnosis of AF (ICD‐10: I48), hospitalisa-
tion or outpatient visit were included from 1 January 2010 
until 1 August 2016 with follow- up to 1 August 2017. The 
diagnosis of AF in the DNPR has a positive predictive 
value of 94.0%.16 Patients with rheumatic valvular heart 
disease or valve interventions were excluded. To allow 
patients time to fill their prescriptions after discharge, a 
10- day wash- out period was used. Due to no data on race/
ethnicity in the The Civil Registration System, we excluded 
immigrants and those with missing information on immi-
gration and presumed Caucasian/European- white for 
non- immigrants. Given complete nationwide coverage of 
DNPR, missing data are not present. For baseline charac-
teristic and outcome comparison, we included the world-
wide enrolled GARFIELD- AF patients and the patients 
enrolled from the Scandinavian sites; Denmark, Sweden, 
Norway and Finland (GARFIELD- AF Scandinavia).
Covariates, GArFIelD-AF model, ChA2DS2-VASc and hAS-bleD
For the Danish AF cohort, all baseline variables were 
defined from ICD-10 codes, as any primary or secondary 
diagnosis, inpatient or outpatient, registered up to 10 years 
prior to the inclusion date. Pharmacotherapy at baseline 
was identified by Anatomical Therapeutic Chemical codes 
of prescription drugs claimed up to 180 days prior to the 
inclusion date. For OAC, within the 180 days, the latest 
prescription filled of either vitamin K antagonist (VKA) 
or non- vitamin K oral anticoagulants (NOAC) was used. 
Prescriptions claimed for antidiabetic drugs were used as 
proxy for diabetes mellitus. Hypertension was defined as 
claimed prescription for a combination of at least two of 
the seven different antihypertensive drug classes as previ-
ously reported.17 The algorithm for GARFIELD- AF 1- year 
risk of ischaemic stroke/systemic embolism (SE) relies 
on the following variables: age (in years), history of isch-
aemic stroke, prior bleeding (any recorded in medical 
records), heart failure (medical history of heart failure 
or ejection fraction of <40%), chronic kidney disease 
(CKD) (stages III–V), race/ethnicity and use of OAC 
(VKA or NOAC). The algorithm for GARFIELD- AF 1- year 
risk of major bleeding/haemorrhagic stroke was devel-
oped in patients taking OAC and involves age, CKD and 
vascular disease, in which the latter is defined as history 
of myocardial infarction (MI) or unstable angina, aortic 
or peripheral artery disease. The CHA2DS2- VASc score is 
composed of age, sex, a history of heart failure, hyper-
tension, stroke, transient ischaemic attack, thromboem-
bolism and/or diabetes. HAS- BLED is composed of age, 
uncontrolled hypertension renal disease, liver disease, 
labile international normalised ratio (INR), medication 
use predisposing to bleeding and a history of stroke, 
major bleeding and/or predisposition to bleeding. All 
covariates were based on ICD-10 codes. The equations for 
these respective scores and ICD-10 codes can be found in 
online supplementary table S1.
Definitions of endpoints
The primary efficacy endpoint for this study involved a 
1- year composite of ischaemic stroke or SE. The primary 
safety endpoint involved a composite of haemorrhagic 
stroke or major bleeding. Major bleeding was defined as 
an organ- specific bleeding requiring hospitalisation.18 A 
list of ICD-10 codes used to compute these definitions can 
be found in Table S2. In the GARFIELD- AF cohorts, the 
occurrence of ‘major bleeding’ was defined according 
to the International Society on Thrombosis and Haemo-
stasis (ISTH) criteria.11 15 19
Patient and public involvement
Patients or the public were not involved in the design of 
the study.
Statistical analyses
For the Danish AF cohort, we stratified baseline charac-
teristics by CHA2DS2- VASc score (≤2 for women, 0–1 for 
men and >2 for women and >1 for men). The Danish AF 
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cohorts were followed for a maximum of 1- year from the 
discharge date and until the event of interest (stroke/SE 
or major bleeding), death, emigration or end of follow- up 
(August 2017). For all three cohorts (Danish AF cohort, 
GARFIELD Scandinavia and GARFIELD Global), 1- year 
absolute risks of stroke/SE and major bleeding were 
estimated non- parametrically using the Aalen- Johansen 
estimator with competing risk of death. For the Danish 
AF cohort, using a logistic regression model, we used 
the original coefficients from the GARFIELD- AF model 
development study. The discriminative performance 
of GARFIELD- AF for predicting ischaemic stroke/SE 
and major bleeding hospitalisations was assessed using 
receiver operating characteristics curves and reported 
as area under the curve (AUC) values. The C- index with 
95% CI was reported as a measure of discrimination. As 
there was no censoring issue because the data did not 
contain any loss to follow- up within the first year of the 
study period, the significance test of C- index differences 
was tested for significance with DeLongs method.20 Cali-
bration was assessed by calculating deciles of predicted 
probabilities and plotting the average predicting with 
the observed Kaplan- Meier rate and 95% CI within each 
decile. A subgroup analysis for stroke prediction was 
undertaken for low risk patients. As a sensitivity analysis, 
we estimated the logistic regression coefficients for each 
individual covariate used in the GARFIELD- AF models. 
Statistical analyses were performed using R software 
(Team RC. R: A Language and Environment for Statistical 
Computing, 2019).
reSultS
From the Danish registries, a total of 110 276 patients 
were diagnosed with AF between 2010 and 2016. Of those 
patients, 91 836 met the inclusion criteria for the study 
(Figure S1). Of these, 70 020 were identified as high risk 
and 20 673 was identified as low risk of stroke/SE. A total 
of 51 180 were on OACs. From the GARFIELD- AF regis-
tries, 52 080 patients with AF were included globally, and 
2396 patients were included from the Scandinavian sites.
Characteristics of study participants
Baseline characteristics for all three cohorts (Danish AF 
cohort, GARFIELD Scandinavia and GARFIELD Global) 
are shown in table 1. Compared with GARFIELD Scandi-
navia, the Danish AF cohort had a more equal represen-
tation of men and women (54% vs 58%) and was older 
(median age 75 vs 73). There were also notable differ-
ences in comorbidities, in which diabetes, hypertension 
and CKD were less prevalent in the Danish AF cohort, 
whereas a history of bleeding (11.6% vs 1.9% vs 2.5%) 
was much more prevalent compared with the GARFIELD 
Scandinavia or global cohorts. Despite these differences, 
the median CHA2DS2Vasc scores were comparable among 
all cohorts but the HAS- BLED median was higher in 
the Danish AF cohort. For the GARFIELD model, the 
median GARFIELD scores were higher in the Danish AF 
cohort than both GARFIELD cohorts. The use of OAC 
therapy was 56.4% in the Danish AF cohort, which was 
lower than the reported percentages in GARFIELD Scan-
dinavia (68.0%) and GARFIELD Global (60.8%). The 
use of aspirin, ADP- inhibitors and non- steroidal anti- 
inflammatory drugs was higher in the Danish AF cohort. 
The characteristics of patients at low risk (CHA2DS2Vasc 
of 0–1 in men and 1–2 in women; n=20 673) and high risk 
(n=70 020) for the Danish AF population are displayed 
in Table S3. The median (IQR) for CHA2DS2- VASc and 
HAS- BLED scores in the high- risk group was 43–5 and 2.2 3
Clinical outcomes at 1-year follow-up
Table 2 displays the number of stroke/SE, major bleeding 
and all- cause mortality for the Danish AF cohort and 
GARFIELD- AF cohort. For the Danish AF cohort, over 
a 1- year follow- up period, a total of 2094 (2.3%) stroke/
SE, 2642 (2.9%) major bleedings were reported. Annual 
mortality rates were high with 10 915 deaths (12.0 per 100 
person years). For the OAC- treated patients, there were 
4521 deaths (8.8 per 100 person years) and for low risk 
patients, there were 623 deaths (3.0 per 100 person years). 
For the GARFIELD- AF Global, the rates of events were lower 
for stroke/SE (1.2%), major bleeding (1.1%) and deaths 
(4.7%). For the GARFIELD- AF Scandinavia, the rates of 
events were 1.0% for stroke/SE, 1.7% for major bleeding 
(1.7%), and 3.7% for deaths. The cumulative incidence for 
ischaemic stroke to 1 year for low- risk and high- risk patients 
are presented in Figure S2 for the Danish AF cohort. The 
cumulative incidence of stroke/SE and ischaemic stroke 
for the Danish AF cohort, GARFIELD Scandinavia and 
GARFIELD Global can be found in figure 1.
external validation of GArFIelD-AF model
The C- index for the GARFIELD- AF model for 1- year stroke 
was 0.71 (95% CI: 0.70 to 0.72) in the overall Danish AF 
cohort of 90 693 patients and 0.64 (95% CI: 0.59 to 0.69) 
in low- risk patients not requiring OAC therapy (n=20 673). 
The C- index for the GARFIELD- AF model for 1- year major 
bleeding risk was 0.64 (95% CI 0.63 to 0.66) in patients using 
OAC therapy. The GARFIELD- AF model for stroke/SE 
and major bleeding scores were both well calibrated in the 
Danish AF cohort (figures 2 and 3). The individual covari-
ates in the GARFIELD- AF model expressed a similar regres-
sion coefficient for most covariates in the Danish cohort 
when compared with the original derivation GARFIELD- AF 
cohort (online supplementary table S4).
GArFIelD-AF model versus ChA2DS2-VASc score for predicting 
stroke/Se
The AUC curves for predicting stroke using the 
GARFIELD model and CHA2DS2- VASc scores are 
displayed in figure 4A for the Danish AF cohort and 
figure 4B for the low risk patients. The AUC and corre-
sponding C- index for GARFIELD was significantly higher 
when compared with CHA2DS2Vasc for predicting stroke 
outcomes, in the overall cohort (C- index: 0.71, 95% CI: 
0.70 to 0.72 vs 0.67, 95% CI: 0.66 to 0.68) as well as in 
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Table 1 Baseline characteristics of patients from the Danish AF cohort, GARFIELD- AF Scandinavia and GARFIELD- AF Global 
registries
Danish AF cohort GARFIELD- AF Scandinavia GARFIELD- AF Global
n 90 693 2396 52 080
Age (median (IQR)) 75 (66.0, 83.0) 73.0 (66.0, 78.0) 71.0 (63.0, 78.0)
Sex, male (%) 48 486 (53.5) 1389 (58.0) 29 068 (55.8)
Race, Caucasian (%) NA 1860 (99.3) 32 028 (63.1)
Diabetes (%) 10 900 (12.0) 387 (16.2) 11 555 (22.2)
Stroke/TIA (%) 12 827 (14.1) 325 (13.6) 3879 (7.5)
SE (%) 448 (0.5) 6 (0.3) 335 (0.6)
History of bleeding (%) 10 544 (11.6) 46 (1.9) 1318 (2.5)
Vascular disease (%) 15 305 (16.9) 268 (11.2) 7682 (14.8)
Chronic kidney disease (%) 4224 (4.7) 185 (7.7) 5360 (10.3)
Heart failure (%) 14 961 (16.5) 348 (14.5) 11 758 (22.6)
Ischaemic heart disease (%) 13 445 (14.8) 331 (13.8) 11 265 (21.6)
Hypertension (%) 55 665 (61.4) 1659 (69.4) 39 643 (76.3)
VTE or PE (%) 5141 (5.7) 77 (3.2) 1355 (2.6)
NOAC (%) 23 212 (25.6) 521 (21.7) 11 004 (21.1)
VKA (%) 27 968 (30.8) 1110 (46.3) 20 708 (39.8)
OAC (%) 51 180 (56.4) 1631 (68.0) 31 712 (60.8)
VKA + AP (%) 10 773 (11.9) 181 (7.6) 4827 (9.4)
NOAC + AP (%) 7608 (8.4) 47 (2.0) 1896 (3.7)
NSAID (%) 13 078 (14.4) 23 (1.0) 1701 (3.3)
Acetylsalicylic acid (%) 32 890 (36.3) 413 (17.2) 14 636 (28.1)
ADP- inhibitor (%) 9128 (10.1) 89 (3.7) 3580 (6.9)
CABG (%) 3291 (3.6) 92 (3.9) 1625 (3.2)
CHA2DS2VASC (median (IQR)) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0)
CHA2DS2VASC (%)   
  0 5678 (6.3) 19 (0.8) 1516 (2.9)
  1 10 231 (11.3) 279 (11.7) 6369 (12.4)
  2 16 137 (17.8) 530 (22.2) 10 230 (19.9)
  3 20 143 (22.2) 626 (26.2) 12 138 (23.6)
  4 19 378 (21.4) 526 (22.1) 11 022 (21.4)
  5 11 020 (12.2) 238 (10.0) 5895 (11.5)
  >5 8106 (8.9) 167 (7.0) 4238 (8.2)
HAS- BLED (median (IQR)) 2.0 (1.0, 3.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)
HAS- BLED category n, missing (%) 1088 (1308) 37 549 (14 531- missing)
  0 8297 (9.1) 169 (15.5) 5471 (14.6)
  1 19 956 (22.0) 507 (46.6) 16 169 (43.1)
  2 31 170 (34.4) 301 (27.7) 11 692 (31.1)
  3 24 998 (27.6) 87 (8.0) 3570 (9.5)
  >3 6272 (6.9) 24 (2.2) 647 (1.7)
GARFIELD- AF model, stroke, median (IQR) 1.10 (0.75, 1.82) 0.80 (0.60, 1.10) 0.90 (0.70, 1.40)
GARFIELD- AF model, bleed, median (IQR) 1.08 (0.74, 1.54) 0.90 (0.70,1.30) 1.00 (0.70, 1.40)
AP, antiplatelet therapy; CABG, coronary artery bypass grafting; GARFIELD- AF, Global Anticoagulant Registry in the FIELD- Atrial Fibrillation; 
NA, Not available; NOAC, non- vitamin- K antagonist; NSAID, non- steroidal anti- inflammatory drug; OAC, oral anticoagulants; PE, pulmonary 
embolism; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin- K antagonist; VTE, venous thromboembolism.
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Table 2 Number of events and deaths for 1- year follow- up in the Danish population (all patients, patients on OAC, low- risk 
patients), GARFIELD- AF Global and GARFIELD- AF Scandinavia
Danish AF 
cohort (n=90 
693)
Patients 
treated with 
OAC (n=51 
180)
Low- risk 
patients 
(n=20 673)
GARFIELD 
Scandinavia 
(n=2396)
GARFIELD- AF Global 
(n=52 080)
Ischaemic Stroke/SE 2094 994 139 24 599
Major bleeding/haemorrhagic 
stroke
2642 1492 242 28* 341†
Deaths 10 915 4521 623 88 2459
Low- risk patients were defined as CHA2DS2- VASc score (≤2 for women, 0–1 for men and >2 for women and >1 for men).
*Of those treated with OAC (n=1631)
†Of those treated with OAC (n=31 712)
AF, atrial fibrillation; GARFIELD- AF, Global Anticoagulant Registry in the FIELD- Atrial Fibrillation; OAC, oral anticoagulation; SE, systemic 
embolism.
Figure 1 Cumulative incidence of stroke/SE (panel A) and major bleeding (panel B) in the Danish AF cohort, GARFIELD- AF 
Scandinavia and GARFIELD- AF Global. AF, atrial fibrillation; GARFIELD- AF, Global Anticoagulant Registry in the FIELD- Atrial 
Fibrillation; SE, systemic embolism.
low- risk patients (C- index: 0.62, 95% CI: 0.59 to 0.69 vs 
0.57, 95% CI: 0.53 to 0.61).
GArFIelD-AF model versus hAS-bleD score for predicting 
major bleeding/haemorrhagic stroke
Figure 4C illustrates the AUC curves for the prediction of 
major bleeding based on the GARFIELD and HAS- BLED 
scores in patients taking OAC therapy. The discrimina-
tory value of GARFIELD was comparable with HAS- BLED: 
C- index: 0.64 (95% CI: 0.63 to 0.66) versus C- index: 0.64 
(95% CI: 0.63 to 0.65), respectively.
Table 3 displays available evidence comparing the 
discriminatory properties of various models for stroke/
SE and major bleeding.
DISCuSSIOn
In a large unselected contemporary Danish AF cohort, 
our study demonstrates that the GARFIELD- AF model 
serves as a reliable risk stratification tool. We found 
that the GARFIELD- AF model surpasses the widely used 
CHA2DS2- VASc score in predicting the risk of stroke, both 
in high- risk and low- risk patients. For predicting major 
bleeding, the three- item GARFIELD- AF model is on par 
with HAS- BLED among anticoagulated patients with AF.
Risk- stratification of patients with AF is essential to miti-
gate the risk of stroke/SE when initiating anticoagulation 
therapy. As such, the easy- to- calculate CHA2DS2- VASc 
score serves as the risk- stratification tool recommended 
by international guidelines to commence therapy when 
the risk of stroke reaches a threshold of >2% per annum.21 
Prior studies have shown that guideline- adherent (risk- 
stratified) anticoagulation therapy is associated with 
a 60%–70% reduction in thromboembolic associated 
complications and mortality.22 Despite these reductions 
in stroke risk, there is still room for improvement in risk 
stratification of patients with AF and anticoagulation 
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Figure 2 Calibration plots of GARFIELD- AF model and stroke/SE risk in overall Danish population (A) and in low- risk patients 
(B). Predicted probability for GARFIELD (blackline), and actual observed cumulative incidence estimates with 95% CI for each 
GARFIELD score in deciles including a linear regression model (dashed line) and LOESS function of observed probability (red 
line). GARFIELD- AF, Global Anticoagulant Registry in the FIELD- Atrial Fibrillation; SE, systemic embolism.
Figure 3 Calibration plots of GARFIELD- AF model 
and major bleeding risk in Danish population. Predicted 
probability for GARFIELD (blackline), and actual observed 
cumulative incidence estimates with 95% CI for each 
GARFIELD score in deciles including a linear regression 
model (dashed line) and LOESS function of observed 
probability (red line). GARFIELD- AF, Global Anticoagulant 
Registry in the FIELD- Atrial Fibrillation.
therapy. In this regard, the GARFIELD- AF model, which 
calculates the risk of stroke, death and major bleeding, 
is promising, particularly as it performed better than the 
CHA2DS2- VASc and HAS- BLED.
11 The GARFIELD- AF 
model is not a risk score that is categorised into risk 
groups but instead it provides risk prediction on a contin-
uous scale. As the model provides risk estimates of stroke/
SE and bleeding (and mortality when blood pressure and 
heart rate data are available) in one single calculation 
based on routinely collected data, it could have poten-
tially wide clinical applications.
Underuse of anticoagulation therapy is a well- known 
problem in particular in high- risk patients.23 Our study 
found that 73.1% of patients with increased stroke risk 
(n=51 180, CHA2DS2-VASc>2 in women and >1 in men) 
received anticoagulation therapy. Studies suggest that 
treatment barriers are based on overestimation of 
bleeding risks (eg, recurrent falls and prior peptic ulcers) 
and lack of reliable risk stratification tools and readily 
available information that does not rely on specific labo-
ratory tests such as HAS- BLED.9 10 23
To provide predictions for bleeding risk, several 
bleeding scores have been developed, of which HAS- 
BLED has been most rigorously tested.24 25 While the 
HAS- BLED risk score is clinically useful to identify 
patients at high bleeding risk, it requires information that 
may not always be available in outpatient and primary 
care settings, such as information on liver function 
tests, INR status and the presence of anaemia. This may 
be a limitation for the implementation of this score in 
low- resource settings and is of relevance as the majority 
(60%) of community- dwelling patients with AF are seen 
in primary care.26 27 Moreover, primary care physicians 
achieve lower anticoagulation rates compared with 
hospital- based physicians.28 29 While there are multiple 
reasons for these differences, which include differences 
in populations, with high percentage of (relative) contra-
indications (40%–65%) and care- related factors, the lack 
of an integral decision tool impedes informed decisions 
on initiating or continuing antithrombotic therapy.10 30
In the present study, the external validation show that 
GARFIELD- AF is well calibrated with the predicted risks, 
and the good calibration aligns well with the original 
GARFIELD- AF derivation cohort.11 GARFIELD- AF score 
has improved discriminatory abilities compared with 
CHA2DS2- VASc score in stroke prediction and on par 
with HAS- BLED for bleeding prediction. To our surprise, 
our external validation of GARFIELD- AF discriminatory 
c- index for stroke prediction was slightly higher (0.71) 
than the c- index in the original GARFIELD cohort 
(0.69). Furthermore, the Danish AF cohorts were older 
with more stroke events than both GARFIELD cohorts 
and higher predicted risk than the GARFIELD cohorts. 
The opposite was the case for major bleeding predic-
tion where the original GARFIELD cohort had better 
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Figure 4 Receiver Operating Characteristic curves of GARFIELD- AF model versus CHA2DS2VASc scores for predicting stroke 
in (A) the Danish AF cohort and (B) low- risk individuals, and (C) GARFIELD- AF model versus HAS- BLED scores for predicting 
major bleeding in the Danish AF cohort in those receiving oral anticoagulants (n=51 180). Low- risk stroke patients were defined 
as CHA2DS2- VASc score (≤2 for women, 0–1 for men and >2 for women and >1 for men). AF, atrial fibrillation; GARFIELD- AF, 
Global Anticoagulant Registry in the FIELD- Atrial Fibrillation.
Table 3 Available evidence comparing the discriminatory properties of various models for stroke/SE and major bleeding11 24
Outcome Cohort N
GARFIELD- AF- AUC (95% 
CI)
CHA2DS2- VASc
/HAS- BLED- AUC (95% 
CI)
Stroke/SE GARFIELD- AF 39 898 0.69 (0.67 to 0.71) 0.64 (0.61 to 0.66)
ORBIT- AF 9743 0.69 (0.64 to 0.75) 0.69 (0.64 to 0.74)
Danish AF cohort 90 693 0.71 (0.70 to 0.72) 0.67 (0.66 to 0.68)
Stroke/SE low risk patients GARFIELD- AF 7882 0.65 (0.56 to 0.73) 0.59 (0.50 to 0.67)
Danish AF cohort 20 673 0.64 (0.59 to 0.69) 0.57 (0.53 to 0.61)
Major bleeding GARFIELD- AF 25 677 0.66 (0.62 to 0.69) 0.64 (0.61 to 0.68)
ORBIT- AF 7442 0.61 (0.58 to 0.64) –
SPORTIF III- V 3550 0.56 (0.54 to 0.57) 0.58 (0.56 to 0.60)
Danish AF cohort 51 180 0.64 (0.63 to 0.66) 0.64 (0.63 to 0.65)
AUC, area under the curve; GARFIELD- AF, Global Anticoagulant Registry in the FIELD- Atrial Fibrillation; ORBIT- AF, The Outcomes Registry for 
Better Informed Treatment of Atrial Fibrillation; SE, systemic embolism; SPORTIF, The Stroke Prevention Using Oral Thrombin Inhibitor in Atrial 
Fibrillation.
discriminatory abilities than HAS- BLED. The significant 
differences in the cohort characteristics, for example, 
higher HAS- BLED and more use of combined OACs and 
antiplatelet therapy in the Danish AF cohort, and defini-
tions of covariates and outcomes are likely to play a key 
role in both instances.
The value of CHA2DS2- VASc score in defining patients 
with a truly low risk of stroke is uncertain, partly because 
the number of patients to accurately assess lower risk 
patients in the original studies was insufficient.12 31 The 
evaluation of the performance of risk scores in this low- 
risk category is important, as it determines the threshold 
when initiating antithrombotic therapy outweighs the 
risk of bleeding. In our study although both models had 
modest predictive discrimination for low- risk patients, we 
found that in these patients, the GARFIELD- AF model 
was well calibrated and provided a better prediction than 
CHA2DS2- VASc score in indicating which patients are 
truly at low risk for subsequent stroke.
limitations and future directions
The primary limitation of this study is that definitions 
are based on administrative ICD-10 codes which are 
prone to non- systematic misclassification bias. Discrep-
ancies exist between the GARFIELD- AF registry and the 
Danish registries in the definitions of comorbidities and 
clinical outcome data. This was most notable for major 
bleeding and stroke/SE events and CKD. In the Danish 
AF cohort, selected ICD-10 codes for bleeding hospital-
isations were applied, whereas GARFIELD- AF applied the 
ISTH criteria for major bleeding, which are more restric-
tive. Apart from differences in disease definitions, the 
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relative high number of bleeding and stroke/SE events 
in the Danish AF cohort could also be explained by site 
of enrolment (only hospital/out- patient). Similar data 
limitations apply to the construction of CHA2DS2- VASc 
score and HAS- BLED scores which was calculated from 
ICD-10 code usage although this study followed the stan-
dards set by other researchers using the same Danish 
registries.17 Specifically, we were unable to account for 
labile INR component of the HAS- BLED score. Another 
limitation was the inability to ascertain ethnicity status 
which is an integrated covariate of the GARFIELD- AF 
model. Therefore, we excluded immigrants to strengthen 
the assumption of European/Caucasian ethnicity in the 
cohort. The GARFIELD Scandinavian cohort consisted 
of 99.3% Caucasians. Population- based studies in other 
more ethnically diverse cohorts are warranted. We did 
not asses net reclassification improvement as this statistic 
is not appropriate when using it for point- based scores, 
such as CHA2DS2- VASc.
32 For the implementation of the 
GARFIELD- AF model, an online risk calculator already 
exists. A next step would be to provide an electronic 
health record integrated solution, in which stroke/SE 
and bleeding risks are automatically calculated when a 
patient is identified with AF. Doing so would promote 
balanced and evidence- based decision- making on antico-
agulation therapy. Integrating the GARFIELD- AF model 
into electronic health records would also provide a way 
for anonymous monitoring of outcomes of patients in 
which the GARFIELD- AF model was applied, which can 
be used to further optimise risk prediction.
COnCluSIOn
The GARFIELD- AF model adequately predicted the risk 
of ischaemic stroke/SE and major bleeding/haemor-
rhagic stroke in a nationwide Danish cohort of contempo-
rary patients with non- valvular AF. Our external validation 
confirms that the performance of the GARFIELD- AF 
model was superior to CHA2DS2VASc in predicting stroke/
SE both in high- risk and in low- risk patients and compa-
rable with HAS- BLED for predicting major bleeding. 
The GARFIELD- AF model holds an advantage over the 
existing risk scores as it permits for simultaneous evalua-
tion of death, stroke and bleeding risks and uses readily 
available clinical parameters. As such, the tool may lead 
to more informed treatment decisions, improve moni-
toring for bleeding complications and improve outcomes 
for patients treated for AF in the community.
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